Advertisement

Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial

  • Christopher M. Tarney
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD
    Search for articles by this author
  • Guisong Wang
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD
    Search for articles by this author
  • Nicholas W. Bateman
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD

    John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD
    Search for articles by this author
  • Kelly A. Conrads
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD
    Search for articles by this author
  • Ming Zhou
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD
    Search for articles by this author
  • Brian L. Hood
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD
    Search for articles by this author
  • Jeremy Loffredo
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD
    Search for articles by this author
  • Chunqiao Tian
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD

    John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD
    Search for articles by this author
  • Kathleen M. Darcy
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD

    John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD
    Search for articles by this author
  • Chad A. Hamilton
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD

    Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, VA
    Search for articles by this author
  • Yovanni Casablanca
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD

    John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD
    Search for articles by this author
  • Anna Lokshin
    Affiliations
    University of Pittsburgh Medical Center, Pittsburgh, PA
    Search for articles by this author
  • Thomas P. Conrads
    Correspondence
    Thomas P. Conrads, PhD.
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD

    John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD

    Inova Schar Cancer Institute, Inova Center for Personalized Health, Falls Church, VA

    Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, VA
    Search for articles by this author
  • G. Larry Maxwell
    Correspondence
    Corresponding author: G. Larry Maxwell MD.
    Affiliations
    Department of Obstetrics and Gynecology, Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD

    John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD

    Inova Schar Cancer Institute, Inova Center for Personalized Health, Falls Church, VA

    Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, VA
    Search for articles by this author

      Background

      Endometrial cancer is the most common gynecological cancer in the United States. However, no early detection test exists for asymptomatic women at average risk for endometrial cancer.

      Objective

      We sought to identify early detection biomarkers for endometrial cancer using prediagnostic serum.

      Study Design

      We performed a nested case-control study of postmenopausal women in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial (n = 78,216), including 112 incident endometrial cancer cases and 112 controls. Prediagnostic serum was immunodepleted of high-abundance proteins and digested with sequencing grade porcine trypsin via pressure cycling technology. Quantitative proteomics and phosphoproteomics was performed using high-resolution liquid chromatography–tandem mass spectrometry and highly multiplexed isobaric mass tag combined with basic reversed-phase liquid chromatography. A set of proteins able to predict cancer status was identified with an integrated score assessed by receiver-operator curve analysis.

      Results

      Mean time from blood draw to endometrial cancer diagnosis was 3.5 years (SD, 1.9 years). There were 47 differentially abundant proteins between cases and controls (P < .05). Protein alterations with high predictive potential were selected by regression analysis and compiled into an aggregate score to determine the ability to predict endometrial cancer. An integrated risk score of 6 proteins was directly related to disease incidence in cases with blood draw ≤2 years, >2 years to ≤5 years or >5 years prior to cancer diagnosis. The integrated score distinguished cases from controls with an area under the curve of 0.80 (95% confidence interval, 0.72–0.88).

      Conclusion

      An integrated score of 6 proteins using prediagnostic serum from the Prostate, Lung, Colorectal, and Ovarian cancer screening trial distinguishes postmenopausal endometrial cancer cases from controls. Validation is needed to evaluate whether this test can improve prediction or detection of endometrial cancer among postmenopausal women.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer Statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Sheikh M.A.
        • Althouse A.D.
        • Freese K.E.
        • et al.
        USA endometrial cancer projections to 2030: should we be concerned?.
        Future Oncol. 2014; 10: 2561-2568
        • American Cancer Society
        Endometrial cancer survival rates, by stage.
        (Available at:)
        • Liu J.R.
        • Conaway M.
        • Rodriguez G.C.
        • Soper J.T.
        • Clarke-Pearson D.L.
        • Berchuck A.
        Relationship between race and interval to treatment in endometrial cancer.
        Obstet Gynecol. 1995; 86: 486-490
        • Matteson K.A.
        • Robison K.
        • Jacoby V.L.
        Opportunities for early detection of endometrial cancer in women with postmenopausal bleeding.
        JAMA Intern Med. 2018; 178: 1222-1223
        • Lacey Jr., J.V.
        • Ioffe O.B.
        • Ronnett B.M.
        • et al.
        Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan.
        Br J Cancer. 2008; 98: 45-53
        • Torres M.L.
        • Weaver A.L.
        • Kumar S.
        • et al.
        Risk factors for developing endometrial cancer after benign endometrial sampling.
        Obstet Gynecol. 2012; 120: 998-1004
        • Lacey Jr., J.V.
        • Sherman M.E.
        • Rush B.B.
        • et al.
        Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.
        J Clin Oncol. 2010; 28: 788-792
        • Prorok P.C.
        • Andriole G.L.
        • Bresalier R.S.
        • et al.
        Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
        Control Clin Trials. 2000; 21: 273S-309S
        • Kondakova I.V.
        • Spirina L.V.
        • Koval V.D.
        • et al.
        Chymotrypsin-like activity and subunit composition of proteasomes in human cancers.
        Mol Biol (Mosk). 2014; 48: 384-389
        • Farias-Eisner G.
        • Su F.
        • Robbins T.
        • Kotlerman J.
        • Reddy S.
        • Farias-Eisner R.
        Validation of serum biomarkers for detection of early- and late-stage endometrial cancer.
        Am J Obstet Gynecol. 2010; 202: 73.e1-73.e5
        • Pejic S.
        • Todorovic A.
        • Stojiljkovic V.
        • Kasapovic J.
        • Pajovic S.B.
        Antioxidant enzymes and lipid peroxidation in endometrium of patients with polyps, myoma, hyperplasia and adenocarcinoma.
        Reprod Biol Endocrinol. 2009; 7: 149
        • Punnonen R.
        • Kudo R.
        • Punnonen K.
        • et al.
        Activities of antioxidant enzymes and lipid peroxidation in endometrial cancer.
        Eur J Cancer. 1993; 29A: 266-269
        • Cocco E.
        • Bellone S.
        • El-Sahwi K.
        • et al.
        Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.
        Br J Cancer. 2009; 101: 335-341
        • Cocco E.
        • Bellone S.
        • El-Sahwi K.
        • et al.
        Serum amyloid A: a novel biomarker for endometrial cancer.
        Cancer. 2010; 116: 843-851
        • Omer B.
        • Genc S.
        • Takmaz O.
        • et al.
        The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.
        Tumour Biol. 2013; 34: 2645-2650
        • Yurkovetsky Z.
        • Ta'asan S.
        • Skates S.
        • et al.
        Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.
        Gynecol Oncol. 2007; 107: 58-65
        • Trabert B.
        • Eldridge R.C.
        • Pfeiffer R.M.
        • et al.
        Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
        Int J Cancer. 2017; 140: 600-610
        • Cao J.
        • Lou S.
        • Ying M.
        • Yang B.
        DJ-1 as a human oncogene and potential therapeutic target.
        Biochem Pharmacol. 2015; 93: 241-250
        • Di Cello A.
        • Di Sanzo M.
        • Perrone F.M.
        • et al.
        DJ-1 is a reliable serum biomarker for discriminating high-risk endometrial cancer.
        Tumour Biol. 2017; 39 (1010428317705746)
        • Kemik P.
        • Saatli B.
        • Yildirim N.
        • et al.
        Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer.
        Gynecol Oncol. 2016; 140: 64-69
        • Diefenbach C.S.
        • Shah Z.
        • Iasonos A.
        • et al.
        Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
        Gynecol Oncol. 2007; 104: 435-442
        • Baser E.
        • Togrul C.
        • Ozgu E.
        • et al.
        Sperm-associated antigen 9 is a promising marker for early diagnosis of endometrial cancer.
        Asian Pac J Cancer Prev. 2013; 14: 7635-7638
        • Yu P.
        • Yan L.
        • Zhang H.
        • Lin X.
        • Zhao X.
        Expression and clinical significance of sperm-associated antigen 9 in patients with endometrial carcinoma.
        Int J Gynecol Cancer. 2012; 22: 87-93
        • Konno R.
        • Takano T.
        • Sato S.
        • Yajima A.
        Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
        Clin Cancer Res. 2000; 6: 3576-3580
        • Tian W.
        • Zhu Y.
        • Wang Y.
        • et al.
        Visfatin, a potential biomarker and prognostic factor for endometrial cancer.
        Gynecol Oncol. 2013; 129: 505-512
        • Scambia G.
        • Benedetti Panici P.
        • Baiocchi G.
        • Perrone L.
        • Greggi S.
        • Mancuso S.
        CA 15-3 as a tumor marker in gynecological malignancies.
        Gynecol Oncol. 1988; 30: 265-273
        • Sood A.K.
        • Buller R.E.
        • Burger R.A.
        • Dawson J.D.
        • Sorosky J.I.
        • Berman M.
        Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome.
        Obstet Gynecol. 1997; 90: 441-447